NCT06797297招募中2 期
A Phase II, Open-label, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal and Acral Melanoma Who Had Not Previously Received Systemic Therapy
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 180
- 试验地点
- 31
- 主要终点
- IRRC-Progression Free Survival(PFS)
研究概览
简要总结
This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic mucosal or acral melanoma who had not previously received systemic therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Participants are assigned to one of two groups in parallel for the duration of the study
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed unresectable, locally advanced or metastatic mucosal or acral-type melanoma, according to the American Joint Committee on Cancer (AJCC) 8th edition stage III-IV.
- •No prior systemic treatment for unresectable or metastatic melanoma; Prior adjuvant or neoadjuvant therapy (except for disease progression to unresectable or metastatic melanoma during adjuvant or neoadjuvant therapy or within 6 months after treatment discontinuation) was permitted.
- •Have at least one measurable lesion (target lesion) according to RECIST v1.
- •For lesions that have previously received radiotherapy or intratumoral injection, measurable lesions that progress to the criteria specified in RECIST1.1 after treatment may be considered.
- •The target lesions of this study must be measured by imaging (enhanced CT or MRI. Plain scan CT or MRI can be accepted after communication with the sponsor if the subjects are allergic to contrast media or have other conditions that are not suitable for enhanced CT or MRI).
- •Skin lesions or other superficial sites that cannot be repeatedly measured by imaging can only be used as non-target lesions.
- •The Eastern Cooperative Oncology Group Physical Status Score (ECOG PS) is 0 or
- •Expected survival time no less than 3 months.
- •Female subjects of childbearing age or male subjects whose partner is a female of childbearing age agree to strictly use effective contraception throughout the treatment period and for 6 months after the treatment period.
- •Breastfeeding women must agree to strictly refrain from breastfeeding during the entire treatment period and for 6 months after the treatment period.
排除标准
- •Women who are pregnant or plan to become pregnant within 6 months before, during, or after the last dose of the study drug.
- •Active or symptomatic central nervous system metastases
- •Any of the following hematological abnormalities were present at baseline * (within 7 days before the first administration of the study drug) :
- •Hemoglobin <90 g/L The absolute count of neutrophils (ANC) was <1.5×10^9/L Platelet count <100×10^9/L
- •Any of the following serum biochemical abnormalities are present at baseline (within 7 days before the first dose) :
- •Total bilirubin >1.5× Upper limit of normal (ULN); Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) >3×ULN; For liver metastasis, AST or ALT > 5.0×ULN; With serum Creatinine >1.5×ULN or Clearance of Creatinine (CCr) <45 mL/min, CCr (using actual body weight) was calculated using Cockcroft-Gault formula (Appendix 3).
- •Albumin <30 g/L.
- •Any of the following coagulation parameters are abnormal at baseline (within 7 days before the first dose) :
- •International normalizaed ratio (INR) >1.5×ULN (>3×ULN if receiving steady dose anticoagulant therapy); Partial thromboplastin time (PTT) (or activated partial thromboplastin time, [activated partial thromboplastin time, PTT) aPTT]) >1.5×ULN (>3×ULN if receiving steady dose anticoagulant therapy).
- •There is a history of active thrombosis or deep vein thrombosis or pulmonary embolism in the 4 weeks prior to initial administration of the investigatory drug, unless the disease is adequately treated and is considered stable by the investigator.
- •Uncontrolled bleeding or a known tendency to bleed.
- •Cardiovascular and cerebrovascular diseases of significant clinical significance.
- •History of interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-related pneumonia, radiation pneumonia, etc. requiring steroid hormone or other treatment, as well as severe abnormal lung function or other forms of restrictive lung disease.
- •An active autoimmune disease requiring systemic treatment (e.g. with disease-modifying drugs, corticosteroids, or immunosuppressants) has occurred within 2 years prior to first administration. Replacement therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic.
研究组 & 干预措施
Experimental: IBI363
Experimental
干预措施: IBI363 (Biological)
Active Comparator: Pembrolizumab
Active Comparator
干预措施: Pembrolizumab (Biological)
结局指标
主要结局
IRRC-Progression Free Survival(PFS)
时间窗: up to 2 years
Progression Free Survival assessed by Independent Radiology Review Committee (IRRC-PFS), Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
次要结局
- Disease Control Rate (DCR)(up to 2 years)
- INV-Progression Free Survival(PFS)(up to 2 years)
- Objective Response Rate (ORR)(up to 2 years)
- Duration of Response (Duration Of Response)(up to 2 years)
- Time to Response (TTR)(up to 2 years)
- Overall Survival (OS)(up to 2 years)
- safety indicators during the treatment(up to 2 years)
研究者
研究点 (31)
Loading locations...
相似试验
已完成
2 期
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerLung Cancer, Non-Small CellNCT01362296GlaxoSmithKline134
撤回
2 期
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04100330AVEO Pharmaceuticals, Inc.
撤回
2 期
Radium 223 Following Intermittent ADTProstate CancerNCT02656563Canadian Urology Research Consortium
已完成
2 期
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCHepatocellular Carcinoma (HCC)NCT03516071Zai Lab (Shanghai) Co., Ltd.90
已完成
2 期
A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT06092762Akeso180